APVO News and Press, Aptevo Therapeutics Inc. From 12/12/22

This week will be one of the most volatile weeks of the year. It won’t matter if you’re trading penny stocks or not, the final round of major economic data and central bank meetings from the FOMC are front and center. We’ve also got another rate hike decision coming and more ...

Aptevo Therapeutics ( NASDAQ: APVO ) on Monday said it had achieved a 100% clinical benefit rate in a phase 1b trial evaluating a combination of its drug candidate APVO436 with cancer medications venetoclax and azacitidine for the treatment of patients with a type of leukemia. Shares ...

Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve Data Demonstrating APVO436 to be Safe and Well-Tolerated and Clinically Active Among AML Patients in Both Combination and Monotherapy Regimens Presented at ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a look at the biggest pre-market stock movers for Monday! Moving stocks are upcoming meetings, clinical trial news, and more. Let’s ...

Aptevo Therapeutics press release ( NASDAQ: APVO ): Q3 GAAP EPS of -$1.50 beats by $0.14 . Aptevo had cash, cash equivalents and restricted cash of $22.6 million as of September 30, 2022. This includes $0.4 million of restricted cash that was released in October 2022. ...

Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and Exposition SEATTLE, WA / ACCESSWIRE / November 10, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company fo...

ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody ALG.APV-527 Rapidly Progressing to Clinical Development for Evaluation in the Treatment of Solid Tumors after Receipt of IND Clearance from the US Food and Drug Administratio...

Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company...

Alligator Bioscience and Aptevo Therapeutics ( NASDAQ: APVO ) said the U.S. Food and Drug Administration had issued a "may proceed" notification to their investigational new drug application for ALG.APV-527 , to treat 5T4-expressing tumor antigens in multiple solid tumor t...

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types LUND, SWEDEN and SEATTLE WA / ACCESSWIRE / September 19, 2022 / Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") today anno...